KIACTA™ is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, a rare disease that results from long-standing inflammatory conditions.
In May 2014, rights were obtained by BELLUS Health’s clinical development partner, Auven Therapeutics, to develop KIACTA™ as a treatment for sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs.
Auven Therapeutics is evaluating the potential use of KIACTA™ for the treatment of patients suffering from active pulmonary sarcoidosis. Auven Therapeutics has developed a clinical Phase 2/3 study protocol to evaluate the safety and efficacy of KIACTA™ in sarcoidosis and an investigational new drug application (IND) for this clinical study could be filed with the U.S. Food and Drug Administration (FDA) in the first quarter of 2017.
The sarcoidosis program is currently under review by Auven Therapeutics and a decision is expected to be made in the coming months.